How big is Evolus, Inc.?

As of Jun 18, Evolus, Inc. has a market capitalization of 596.40 million and reported net sales of 275.47 million with a net profit of -56.20 million over the latest four quarters.

As of Jun 18, Evolus, Inc. has a market capitalization of 596.40 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 275.47 million, while the sum of Net Profit for the same period is -56.20 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 5.52 million and Total Assets at 232.57 million.

What does Evolus, Inc. do?

Evolus, Inc. is a medical aesthetics company specializing in aesthetic procedures and treatments, with recent net sales of $69 million and a net loss of $19 million. It has a market cap of $596.40 million and operates in the Pharmaceuticals & Biotechnology industry.

Overview: <BR>Evolus, Inc. is a medical aesthetics company focused on providing physicians and aesthetic procedures and treatments within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 69 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -19 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 596.40 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -8.46 <BR>Return on Equity: 733.71% <BR>Price to Book: -90.31<BR><BR>Contact Details: <BR>Address: 520 Newport Center Dr Ste 1200, NEWPORT BEACH CA: 92660-7022 <BR>Tel: ['1 949 2844555', '1 646 5367035'] <BR>Fax: 1 302 6365454 <BR>Website: https://www.evolus.com

Should I buy, sell or hold Evolus, Inc.?

Who are in the management team of Evolus, Inc.?

As of March 2022, the management team of Evolus, Inc. includes Chairman Vikram Malik, CEO David Moatazedi, and several directors: Simone Blank, Peter Farrell, David Gill, Robert Hayman, and Karah Parschauer. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Evolus, Inc. includes the following individuals:<BR><BR>- Mr. Vikram Malik, Chairman of the Board<BR>- Mr. David Moatazedi, President, Chief Executive Officer, and Director<BR>- Ms. Simone Blank, Director<BR>- Dr. Peter Farrell, Independent Director<BR>- Mr. David Gill, Independent Director<BR>- Mr. Robert Hayman, Independent Director<BR>- Ms. Karah Parschauer, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Is Evolus, Inc. overvalued or undervalued?

Evolus, Inc. is currently considered risky and overvalued due to troubling financial metrics, including a Price to Book Value of -98.02 and a P/E ratio of -8.2365, alongside a significant stock return decline of -60.42% over the past year compared to the S&P 500's 17.14% return.

As of 12 August 2019, the valuation grade for Evolus, Inc. moved from does not qualify to risky, indicating a significant shift in its financial standing. The company appears to be overvalued, particularly given its troubling financial metrics, including a Price to Book Value of -98.02, an EV to EBIT of -19.61, and an EV to EBITDA of -23.65. These ratios suggest that the company's valuation is not supported by its financial performance.<BR><BR>In comparison to its peers, Evolus, Inc. has a P/E ratio of -8.2365, while PetIQ, Inc. holds a fair valuation with a P/E ratio of 27.1022, highlighting a stark contrast in market perception. Additionally, Repare Therapeutics, Inc. does not qualify for a valuation, further emphasizing the challenges Evolus faces in its industry. Over the past year, Evolus has underperformed significantly, with a stock return of -60.42% compared to the S&P 500's return of 17.14%, reinforcing the notion that the stock is overvalued in its current state.

Is Evolus, Inc. technically bullish or bearish?

As of August 5, 2025, Evolus, Inc. has shifted to a bearish trend, supported by negative indicators such as bearish MACD readings, Bollinger Bands, and moving averages, along with a year-to-date return of -41.85% compared to the S&P 500's 12.22%.

As of 5 August 2025, the technical trend for Evolus, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators supporting this view including bearish MACD readings on both weekly and monthly time frames, bearish Bollinger Bands, and a bearish daily moving average. The KST is also bearish on both weekly and monthly levels, while the Dow Theory indicates a mildly bearish stance on the weekly chart. Additionally, the stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -41.85% compared to the S&P 500's 12.22%.